Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings
February 02 2024 - 7:00AM
Pixium Vision announces the rejection of
the sale plan (plan de cession)
by the Court and the conversion of the receivership proceedings
into liquidation proceedings
Paris, France, February 2,
2024 – 02:00 p.m.
(CET) – Pixium Vision SA (Euronext Growth Paris -
FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing
innovative vision systems to enable patients who have lost their
sight to live more independent lives, announces the decision of the
Paris Commercial Court, by a judgment of January 31, 2024, to
reject the sale plan (plan de cession) presented by the company
NeuroTech Vision, a wholly-owned subsidiary of NeuroTech Vision
LLC, which is itself controlled by Priveterra Capital.
Pixium announces that the Paris Commercial Court
has pronounced in a judgment of the same day, the conversion of the
Company's receivership proceedings, opened by a judgment of
November 13, 2023, into judicial liquidation proceedings.
Given the opening of judicial liquidation
proceedings, there will be no resumption of the listing, and
Euronext will soon proceed with the delisting of Pixium
shares.About Pixium Vision
Pixium Vision is creating a
world of bionic vision for those who have lost their sight,
enabling them to regain visual perception and greater autonomy.
Pixium Vision’s bionic vision systems are associated with a
surgical intervention and a rehabilitation period. Prima System
sub-retinal miniature photovoltaic wireless implant is in clinical
testing for patients who have lost their sight due to outer retinal
degeneration, initially for atrophic dry age-related macular
degeneration (dry AMD). Pixium Vision collaborates closely with
academic and research partners, including some of the most
prestigious vision research institutions in the world, such as
Stanford University in California, Institut de la Vision in Paris,
Moorfields Eye Hospital in London, Institute of Ocular Microsurgery
(IMO) in Barcelona, University hospital in Bonn, and UPMC in
Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies
as “Entreprise Innovante” by Bpifrance.
For more information:
http://www.pixium-vision.com/fr
Follow us on @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
Investor
RelationsPixium VisionOffer NonhoffChief
Financial Officerinvestors@pixium-vision.com |
Media
Relations Rose Piquante ConsultingSophie
BaumontSophie.baumont@rosepiquante-consulting.com+33 6 27 74 74
49 |
- Pixium - Conversion into liquidation proceedings -
01.02.2024
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From Apr 2024 to May 2024
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From May 2023 to May 2024